Glomerulonephritis, Membranoproliferative - 10 Studies Found
Completed |
: Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis : Glomerulonephritis, Membranoproliferative : 2006-01-10 : Drug: Rituximab The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses |
Active, not recruiting |
: Eculizumab in Primary MPGN : Membranoproliferative Glomerulonephritis : 2014-03-17 : Drug: Eculizumab Other Name: Soliris |
Not yet recruiting |
: Daratumumab in Treatment of PGNIMD and C3 GN : Membranoproliferative Glomerulonephritis : 2017-03-20 : Drug: Daratumumab Open-label Other Name: Darzalex |
Completed |
: BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis :
: 1999-11-03 : Drug: BG9588 |
Not yet recruiting |
: A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN :
|
Terminated |
: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease :
|
Withdrawn |
: TP10 Use in Patients With C3 Glomerulopathy (C3G) : Dense Deposit Disease : 2014-11-05 : Drug: TP10 All patients will be enrolled through the University of Iowa. This study will follow a patien |
Withdrawn |
: Sulodexide Treatment in Patients With Dense Deposit Disease : Dense Deposit Disease : 2007-12-20 : Drug: Sulodexide 200 mg per day in an oral gelcap form |
Recruiting |
: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 :
|